225 related articles for article (PubMed ID: 25693667)
21. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
Jones MP; Hruby G; Metser U; Sridharan S; Capp A; Kumar M; Gallagher S; Rutherford N; Holder C; Oldmeadow C; Martin J
Radiat Oncol; 2019 Aug; 14(1):140. PubMed ID: 31387597
[TBL] [Abstract][Full Text] [Related]
23.
Nakajo M; Jinguji M; Shinaji T; Tani A; Nakabeppu Y; Nakajo M; Nakajo A; Natsugoe S; Yoshiura T
Br J Radiol; 2019 Feb; 92(1094):20180620. PubMed ID: 30273012
[TBL] [Abstract][Full Text] [Related]
24. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
[TBL] [Abstract][Full Text] [Related]
25. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.
Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495
[TBL] [Abstract][Full Text] [Related]
26. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
[TBL] [Abstract][Full Text] [Related]
29. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
30. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
31. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
[TBL] [Abstract][Full Text] [Related]
32. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
33. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
[TBL] [Abstract][Full Text] [Related]
35. Dual-time point
Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
[TBL] [Abstract][Full Text] [Related]
36. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
[TBL] [Abstract][Full Text] [Related]
37. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM
AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a diagnostic
Lim CH; Seok HY; Hyun SH; Moon SH; Cho YS; Lee KH; Kim BT; Choi JY
Clin Radiol; 2019 Mar; 74(3):207-215. PubMed ID: 30638733
[TBL] [Abstract][Full Text] [Related]
39. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
40. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]